Phase IIa trial of BGB 324 in patients with chronic myeloid leukaemia

Trial Profile

Phase IIa trial of BGB 324 in patients with chronic myeloid leukaemia

Planning
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2014

At a glance

  • Drugs BGB 324 (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors BerGenBio
  • Most Recent Events

    • 23 Dec 2014 This phase IIa trial in patients with CML is being planned, according to the BerGenBio pipeline.
    • 23 Dec 2014 New trial record
    • 15 Dec 2014 This trial is expected to start in 2015, according to a BerGenBio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top